Losartan Potassium Tablets, 25 Mg Tablet
Product Images NDC 63629-2426

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium Tablets, 25 Mg (NDC 63629-2426). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Figure1)

A line graph comparing the percentage of patients with primary endpoint events over 66 months between two treatments: Atenolol (dotted line) and Losartan Potassium (solid line). The x-axis represents study months, and the y-axis shows the percentage of patients. An annotation indicates an adjusted risk reduction of 13% with a p-value of 0.021 for Losartan Potassium.*

FDA Label Image

Figure 2 (Figure2)

A line graph comparing the percentage of patients experiencing fatal or non-fatal stroke over study months, showing two lines for Atenolol and Losartan Potassium. The graph highlights an adjusted risk reduction of 25% with Losartan Potassium compared to Atenolol, with a p-value of 0.001.*

FDA Label Image

Figure 3 (Figure3)

A clinical study figure presenting hazard ratio forest plots comparing Losartan and Atenolol for primary endpoint events and stroke (fatal/non-fatal) across demographic subgroups. It includes event rates for age, gender, race, ischemic heart status, diabetes, and cardiovascular history, illustrating treatment outcomes and confidence intervals.*

FDA Label Image

Figure 4.jpg (Figure4)

A line chart comparing the percentage of patients with an event over a 48-month period between two groups: those treated with Losartan Potassium and those given a placebo. The graph shows time in months on the x-axis and percent of patients with the event on the y-axis, indicating a risk reduction of 16.1% for Losartan Potassium compared to placebo.*

FDA Label Image

Label (Lbl636292426)

Label for Losartan Potassium Tablets, USP 25 mg by BRP Pharmaceuticals. The label displays the NDC 63629-2426-1, dosage strength 25 mg in a bold black-bordered box, and indicates a package size of 1000 tablets. It includes storage and safety instructions along with manufacturer and relabeler information.*

FDA Label Image

Losartan Potassium, Usp (Structure)

Chemical structure of losartan potassium displayed as a molecular diagram showing the arrangement of atoms and bonds, including the potassium ion (K+).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.